Difference between revisions of "Iptacopan (Fabhalta)"
m |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/soliris-eculizumab-342875 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)] | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/soliris-eculizumab-342875 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)] | ||
| − | == | + | ==Preliminary data== |
*[[Paroxysmal nocturnal hemoglobinuria]] | *[[Paroxysmal nocturnal hemoglobinuria]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Also known as== | ==Also known as== | ||
| Line 19: | Line 14: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Factor B inhibitors]] | [[Category:Factor B inhibitors]] | ||
| − | [[Category:Paroxysmal nocturnal hemoglobinuria medications]] | + | [[Category:Paroxysmal nocturnal hemoglobinuria medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 01:57, 28 December 2022
General information
Class/mechanism: orally bioavailable, highly potent and highly selective factor B inhibitor. Blocks the alternative pathway of complement upstream of both CD55 and CD59. Iptacopan is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH).
Route: oral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp)
Preliminary data
Also known as
- Code name: LNP023